PLANTATION, Fla., Jan. 19 /PRNewswire-FirstCall/ -- Viragen, Inc.
(Amex: VRA) today announced that the Company has entered into an investment
banking agreement, appointing Janney Montgomery Scott LLC ("Janney") as its
financial advisor. Janney will act on Viragen's behalf to evaluate strategic
alternatives, including obtaining additional financing and exploring potential
merger & acquisition opportunities to enhance stockholder value.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a
biotechnology company engaged in the research, development, manufacture and
commercialization of pharmaceutical proteins for the treatment of viral
diseases and cancers. Our product portfolio includes: Multiferon(R) (multi-
subtype, natural human alpha interferon) targeting a broad range of infectious
and malignant diseases; and humanized monoclonal antibodies targeting specific
antigens over-expressed on many types of cancers. We are also pioneering the
development of Avian Transgenic Technology, with the renowned Roslin
Institute, as a revolutionary manufacturing platform for the large-scale,
efficient and economical production of human therapeutic proteins and
antibodies.
About Janney Montgomery Scott:
Janney Montgomery Scott LLC is a major regional full-service investment
bank headquartered in Philadelphia, serving a national client base of emerging
growth and middle market companies. Janney's Healthcare Investment Banking
Group assists life sciences clients in all aspects of raising capital through
private placements and public offerings and also provides strategic advisory
services in areas such as mergers & acquisitions, fairness opinions and
partnering discussions. Janney traces its roots to 1832 and holds the second
oldest seat on the New York Stock Exchange. Janney is a subsidiary of the
Penn Mutual Life Insurance Company, one of the 15 largest mutual insurance
companies in the nation, with assets of more than $13 billion.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
